| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | <1 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | <1 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | <1 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | <1 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | <1 mi |
| Preventing Alzheimer's With Cognitive Training | Phase 3 | University of South Florida | <1 mi |
| Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia | — | GAP Innovations, PBC | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | <1 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | <1 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | <1 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation | Phase 1 | Kestrel Therapeutics, Inc. | <1 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Phase 1/2 | BioNTech SE | <1 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | <1 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | <1 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | <1 mi |
| Lay-Delivered Behavioral Activation in Senior Centers | N/A | University of Washington | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | <1 mi |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | — | SWOG Cancer Research Network | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Phase 1/2 | Milton S. Hershey Medical Center | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Neuroblastoma Maintenance Therapy Trial | Phase 2 | Giselle Sholler | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Phase 2 | Giselle Sholler | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| Clinical Trial on Agitation in Alzheimer's Dementia | Phase 2 | IGC Pharma, LLC | <1 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | <1 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Phase 2 | Innate Pharma | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | <1 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | <1 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance | Phase 2 | White River Junction Veterans Affairs Medical Center | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | <1 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | <1 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | <1 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | <1 mi |
| TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) | N/A | P+F Products + Features USA Inc. | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Phase 2 | Boehringer Ingelheim | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | <1 mi |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | Phase 2 | St. Jude Children's Research Hospital | <1 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| BMT-CARE: Psychosocial Intervention for Transplant Caregivers | N/A | Massachusetts General Hospital | <1 mi |
| A Study of TAK-505 in Adults With Solid Tumors | Phase 1/2 | Takeda | <1 mi |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Phase 1/2 | Milton S. Hershey Medical Center | <1 mi |
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Phase 1 | Celyad Oncology SA | <1 mi |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Phase 1/2 | Pyxis Oncology, Inc | <1 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | <1 mi |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | — | Blueprint Medicines Corporation | <1 mi |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Study of BGB-11417 in Participants With Myeloid Malignancies | Phase 1/2 | BeiGene | <1 mi |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | Phase 1/2 | Theravectys S.A. | <1 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| ColoCare Study - Colorectal Cancer Cohort | — | University of Utah | <1 mi |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | <1 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | <1 mi |
| Outreach Core Activities | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Phase 3 | SOFIE | <1 mi |
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | Phase 1 | Hanmi Pharmaceutical Company Limited | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| Caris Biorepository Research Protocol | — | Caris Science, Inc. | <1 mi |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | <1 mi |
| Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | — | Washington University School of Medicine | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) | Phase 3 | Merus B.V. | <1 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | <1 mi |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | Phase 1/2 | BlueSphere Bio, Inc | <1 mi |
| Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Phase 2 | Genmab | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | <1 mi |
| Biomarkers to Predict Cancer Therapy-related Cardiotoxicity | — | Mayo Clinic | <1 mi |
| A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | Phase 2 | Elevar Therapeutics | <1 mi |
| Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB) | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | Phase 1 | AstraZeneca | <1 mi |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | <1 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | <1 mi |
| REtroperitoneal SArcoma Registry: an International Prospective Initiative | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | <1 mi |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | <1 mi |
| IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase 2 | Fred Hutchinson Cancer Center | <1 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Phase 1 | AstraZeneca | <1 mi |
| Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) | N/A | University of South Florida | <1 mi |
| Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Phase 1/2 | Genfit | <1 mi |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | Phase 2 | City of Hope Medical Center | <1 mi |
| Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2/3 | TuHURA Biosciences, Inc. | <1 mi |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | <1 mi |
| Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens | N/A | ARTIDIS AG | <1 mi |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC) | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Phase 1 | Syndax Pharmaceuticals | <1 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | <1 mi |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Takeda | <1 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | <1 mi |
| Beat Childhood Cancer Specimen Banking and Data Registry | — | Giselle Sholler | <1 mi |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Phase 1 | Oxford BioTherapeutics Ltd | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Syncromune, Inc. | <1 mi |
| Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | Phase 1/2 | CivaTech Oncology | <1 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | <1 mi |
| Axitinib + Ipilimumab in Advanced Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | Phase 2 | Wugen, Inc. | <1 mi |
| Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | Phase 3 | Institute of Cancer Research, United Kingdom | <1 mi |
| Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Phase 1 | Stelexis BioSciences | <1 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Phase 2/3 | Janssen Research & Development, LLC | <1 mi |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | <1 mi |
| Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | Phase 2 | John Sfakianos | <1 mi |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | Phase 2 | Tiago Biachi de Castria | <1 mi |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 2 | Orca Biosystems, Inc. | <1 mi |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | <1 mi |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | Phase 2 | Fred Hutchinson Cancer Center | <1 mi |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | Phase 1/2 | AstraZeneca | <1 mi |
| Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | Phase 1/2 | Ossium Health, Inc. | <1 mi |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Phase 1/2 | Alexion Pharmaceuticals, Inc. | <1 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | Phase 3 | J-Pharma Co., Ltd. | <1 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | <1 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | <1 mi |
| A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 | — | University of Washington | <1 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | <1 mi |
| BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Phase 1/2 | Bold Therapeutics, Inc. | <1 mi |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | AstraZeneca | <1 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | Vor Biopharma | <1 mi |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Phase 2/3 | Linnaeus Therapeutics, Inc. | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | <1 mi |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | Phase 1 | AstraZeneca | <1 mi |
| A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma | N/A | Alpha Tau Medical LTD. | <1 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| Study of REM-422 in Patients With AML or Higher Risk MDS | Phase 1 | Remix Therapeutics | <1 mi |
| Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | N/A | Dartmouth-Hitchcock Medical Center | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | <1 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Phase 1 | BlossomHill Therapeutics | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | <1 mi |
| Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| Exercise Prehabilitation for Locoregional Esophageal Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Phase 2 | Taiho Oncology, Inc. | <1 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | <1 mi |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Phase 1 | Celyad Oncology SA | <1 mi |
| Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology) | N/A | Medtronic - MITG | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | Phase 1 | Tetragon Biosciences Ltd | <1 mi |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | <1 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | <1 mi |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Cybrexa Therapeutics | <1 mi |
| Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | Massachusetts General Hospital | <1 mi |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | Phase 1/2 | AstraZeneca | <1 mi |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 1 | Orca Biosystems, Inc. | <1 mi |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | Phase 3 | CarThera | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy | N/A | University of South Florida | <1 mi |
| Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) | — | University of Colorado, Denver | <1 mi |
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Phase 1/2 | Debiopharm International SA | <1 mi |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1 | Hoffmann-La Roche | <1 mi |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | <1 mi |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | <1 mi |
| Galleri® in the Medicare Population. | N/A | GRAIL, Inc. | <1 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | <1 mi |
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Phase 2 | Theradex | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | <1 mi |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | Phase 3 | Eleison Pharmaceuticals LLC. | <1 mi |
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | — | Immune Oncology Research Institute | <1 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | <1 mi |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC | Phase 2 | ImmVira Pharma Co. Ltd | <1 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | <1 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | <1 mi |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | Phase 2/3 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | <1 mi |
| Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Multicenter HomeVENT: Home Values and Experiences Navigation Track | N/A | Johns Hopkins University | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Phase 3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | <1 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | <1 mi |
| A Global Study of the PETAL Consortium | — | Massachusetts General Hospital | <1 mi |
| Longitudinal Bladder Cancer Study for Tumour Recurrence | — | Pacific Edge Limited | <1 mi |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| A First-in-Human Study of FID-022 in Solid Tumor Patients | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Phase 1/2 | AbbVie | <1 mi |
| Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS) | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | SystImmune Inc. | <1 mi |
| Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | <1 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | <1 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | <1 mi |
| Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | <1 mi |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | Phase 1 | TuHURA Biosciences, Inc. | <1 mi |
| KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting | Phase 2 | Kumquat Biosciences Inc. | <1 mi |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Phase 2 | T. John Winhusen, PhD | <1 mi |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | Phase 1 | Solu Therapeutics, Inc | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S) | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | <1 mi |
| Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | <1 mi |
| Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Phase 1 | Crossbow Therapeutics, Inc. | <1 mi |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Phase 1 | Xencor, Inc. | <1 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | AstraZeneca | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | Phase 2 | Oncoinvent Solutions AS | <1 mi |
| Avapritinib With Decitabine in Patients With SM-AHN | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis | Phase 1/2 | ImmunAbs Inc. | <1 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| BCL2i CLAG-M in R/R Acute Myeloid Leukemia | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | <1 mi |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | <1 mi |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Phase 2 | NMD Pharma A/S | <1 mi |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | Phase 3 | Eastern Cooperative Oncology Group | <1 mi |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Phase 3 | Soligenix | <1 mi |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Phase 2 | University of Michigan Rogel Cancer Center | <1 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | <1 mi |
| Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | <1 mi |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | Phase 3 | Rakuten Medical, Inc. | <1 mi |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | <1 mi |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS | Phase 1 | Marker Therapeutics, Inc. | <1 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | <1 mi |
| Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | N/A | Medtronic - MITG | <1 mi |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | <1 mi |
| Twiist Postmarket Surveillance Study for Type 1 Diabetes | — | Deka Research and Development | <1 mi |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Phase 3 | Eli Lilly and Company | <1 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic MiniMed, Inc. | <1 mi |
| A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | Phase 3 | Pfizer | <1 mi |
| T1D Pregnancy & Me | — | Jaeb Center for Health Research | <1 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| Pharmacist-Led Continuous Glucose Monitoring for Prediabetes | — | University of South Florida | <1 mi |
| Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes | N/A | UNC Lineberger Comprehensive Cancer Center | <1 mi |
| Study of Enhanced Programming Stimulation with the Enterra® Therapy System | N/A | Enterra Medical, Inc. | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| Pharmacist-led Continuous Glucose Monitoring | — | University of South Florida | <1 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| Cocooned Moms Study | N/A | InovCares Connected Comprehensive Healthcare Corporation | <1 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | <1 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Phase 4 | Neurocrine Biosciences | <1 mi |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Phase 3 | Eli Lilly and Company | <1 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics | N/A | University of South Florida | <1 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | <1 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | <1 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease | N/A | InSightec | <1 mi |
| Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP) | N/A | University of South Florida | <1 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | <1 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | MapLight Therapeutics | <1 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass | N/A | Boston Scientific Corporation | <1 mi |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | Corxel Pharmaceuticals | <1 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | <1 mi |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | <1 mi |
| A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | N/A | Cleerly, Inc. | <1 mi |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Phase 2 | Retension Pharmaceuticals. Inc. | <1 mi |
| Clinical Course Of Disease In Participants With FA-CM | — | Lexeo Therapeutics | <1 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Ultrafiltration Versus IV Diuretics in Worsening Heart Failure | N/A | Nuwellis, Inc. | <1 mi |
| CCM OPEN HF Registry | — | Impulse Dynamics | <1 mi |
| AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM | — | Cordio Medical | <1 mi |
| Breaking Fasts Ahead of Cardiac Caths | N/A | University of South Florida | <1 mi |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study | N/A | Vektor Medical | <1 mi |
| Observational Study Designed to Detect Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device | — | CHFDX,Inc. | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | <1 mi |
| Encore PFO Closure Device - The PerFOrm Trial | N/A | Encore Medical Inc. | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | <1 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Phase 2 | Tectonic Therapeutic | <1 mi |
| CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry | — | Universitätsklinikum Hamburg-Eppendorf | <1 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | <1 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | <1 mi |
| Tracking Results of Ablations to Combat AF Registry Generation 2 | — | AtriCure, Inc. | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | <1 mi |
| Physio-Anatomy Clinical Data Collection Study | — | Gentuity, LLC | <1 mi |
| Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study | Phase 2 | University of South Florida | <1 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | <1 mi |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Phase 2 | Kymera Therapeutics, Inc. | <1 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Phase 3 | Generate Biomedicines | <1 mi |
| Feasibility of a Smartphone Application for Asthma Self-management | N/A | University of South Florida | <1 mi |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | Phase 2 | Eli Lilly and Company | <1 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | <1 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Phase 3 | Generate Biomedicines | <1 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | <1 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | <1 mi |
| A Study of SPY072 in Rheumatic Disease | Phase 2 | Spyre Therapeutics, Inc. | <1 mi |
| ARVIS TKA vs Conventional TKA | N/A | Foundation for Orthopaedic Research and Education | <1 mi |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | Phase 2 | AbbVie | <1 mi |
| Safety and Effectiveness of the HIT Reverse HRS | N/A | Hip Innovation Technology | <1 mi |
| Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty) | — | Zimmer Biomet | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | <1 mi |
| Exactech Shoulder Post Market Clinical Follow-up Study | — | Exactech | <1 mi |
| Sustained Acoustic Medicine for Osteoarthritis Pain | Phase 1 | ZetrOZ, Inc. | <1 mi |
| A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension | — | Canary Medical | <1 mi |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Phase 2/3 | Olatec Therapeutics LLC | <1 mi |
| Woodcasting Versus Thermoplast Splint in CMC Arthroplasty | N/A | Foundation for Orthopaedic Research and Education | <1 mi |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) | Phase 2 | Protalix | <1 mi |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| The KinematX Midcarpal Total Wrist Arthroplasty Registry | — | Extremity Medical | <1 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | <1 mi |
| Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis | Phase 1 | Foundation for Orthopaedic Research and Education | <1 mi |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Eli Lilly and Company | <1 mi |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | Phase 2 | AstraZeneca | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | <1 mi |
| A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | Phase 2 | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| RE104 Safety and Efficacy Study in Generalized Anxiety Disorder | Phase 2 | Reunion Neuroscience Inc | <1 mi |
| A Study of NTX-1472 in Social Anxiety Disorder | Phase 2 | Newleos Therapeutics, Inc. | <1 mi |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | <1 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | <1 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | <1 mi |
| A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | — | Bayer | <1 mi |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | — | Boston Scientific Corporation | <1 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | <1 mi |
| A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations | Phase 2 | Appello Pharmaceuticals, Inc. | <1 mi |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Phase 2 | Zenas BioPharma (USA), LLC | <1 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | <1 mi |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | <1 mi |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | Phase 1/2 | AstraZeneca | <1 mi |
| Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis | Phase 2 | Autolus Limited | <1 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) | Phase 1 | AbbVie | <1 mi |
| A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | Phase 2 | Ventus Therapeutics U.S., Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | Phase 1 | Hoffmann-La Roche | <1 mi |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | TG Therapeutics, Inc. | <1 mi |
| Dry Needling in Multiple Sclerosis | N/A | University of South Florida | <1 mi |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Phase 2 | Celgene | <1 mi |
| A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | Phase 2 | Hoffmann-La Roche | <1 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) | — | RPCR, Inc. | <1 mi |
| Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer | Phase 3 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | Phase 1 | Regor Pharmaceuticals Inc. | <1 mi |
| The PREDICT Registry: | — | PreludeDx | <1 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | <1 mi |
| Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | <1 mi |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | <1 mi |
| DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| Study of Screening Brain MRIs in Stage IV Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| ILR to Prevent BRCL_MCC 23608 | N/A | University of South Florida | <1 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | <1 mi |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Phase 1 | Senhwa Biosciences, Inc. | <1 mi |
| Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Phase 1/2 | Phoenix Molecular Designs | <1 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | <1 mi |
| Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis | — | University of Hawaii | <1 mi |
| Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Phase 2 | Roswell Park Cancer Institute | <1 mi |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Phase 1/2 | Ellipses Pharma | <1 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| The MIND-BC Study: MIND Diet for Breast Cancer Cognition | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | <1 mi |
| Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | Phase 1 | QuantumLeap Healthcare Collaborative | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Phase 2 | Dogwood Therapeutics Inc. | <1 mi |
| Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers | N/A | City of Hope Medical Center | <1 mi |
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | Phase 1 | Pfizer | <1 mi |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | <1 mi |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | Phase 2 | AbbVie | <1 mi |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | <1 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | <1 mi |
| Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Phase 2 | Teligene US | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Phase 3 | InSightec | <1 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | <1 mi |
| Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | N/A | AIDS Malignancy Consortium | <1 mi |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Phase 1/2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | — | Lung Cancer Mutation Consortium | <1 mi |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | <1 mi |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | Phase 1 | ALX Oncology Inc. | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Phase 1 | Amgen | <1 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | <1 mi |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Phase 2 | Boehringer Ingelheim | <1 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | <1 mi |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In | Phase 3 | ImmunityBio, Inc. | <1 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | <1 mi |
| Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Phase 2 | Greg Durm, MD | <1 mi |
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1/2 | BioNTech SE | <1 mi |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Phase 1 | Memgen, Inc. | <1 mi |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Phase 2/3 | BioNTech SE | <1 mi |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Phase 1 | Bicara Therapeutics | <1 mi |
| SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Phase 1 | Verismo Therapeutics | <1 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | <1 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Phase 2 | Apollomics Inc. | <1 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Phase 1/2 | Simcha IL-18, Inc. | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | <1 mi |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment | Phase 2 | BioNTech SE | <1 mi |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | Arvinas Inc. | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease | N/A | AdventHealth | <1 mi |
| A Study of Efimosfermin Alfa in Adults With Hepatic Impairment | Phase 1 | GlaxoSmithKline | <1 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function | Phase 1 | Aligos Therapeutics | <1 mi |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Phase 3 | Bausch Health Americas, Inc. | <1 mi |
| Multi-analyte Blood Test Clinical Trial | — | Helio Genomics | <1 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | <1 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | <1 mi |
| Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | <1 mi |
| Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune, Inc. | <1 mi |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Crinetics Pharmaceuticals Inc. | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | 7 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | 10 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | 10 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 10 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | 10 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 10 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | 10 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | 10 mi |
| Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | Phase 3 | University of Pennsylvania | 10 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | 10 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | 11 mi |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | OSE Immunotherapeutics | 11 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | 11 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | 11 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | 11 mi |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | Novartis Pharmaceuticals | 11 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | 11 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | 15 mi |
| SPYRAL GEMINI Pilot Study | N/A | Medtronic Vascular | 15 mi |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease | Phase 3 | Vor Biopharma | 16 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | 17 mi |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Phase 2 | Eli Lilly and Company | 17 mi |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 | Genmab | 18 mi |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Phase 3 | Zai Lab (Shanghai) Co., Ltd. | 18 mi |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 18 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | 18 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | 18 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| Study of STP938 in Advanced Solid Tumours | Phase 1 | Step Pharma, SAS | 18 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | 18 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | 18 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | 18 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 18 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | 18 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | 18 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | 18 mi |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | 18 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | 18 mi |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | 18 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | 18 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | 18 mi |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | Phase 1/2 | Jiangsu HengRui Medicine Co., Ltd. | 18 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | 18 mi |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 18 mi |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | 18 mi |
| Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer | N/A | Johns Hopkins All Children's Hospital | 18 mi |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Incyte Corporation | 18 mi |
| International Pediatric Adrenocortical Tumor Registry | — | St. Jude Children's Research Hospital | 18 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | 18 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | 18 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | 18 mi |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | Phase 3 | Grifols Therapeutics LLC | 18 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | 18 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 18 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | 18 mi |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | Phase 2 | Mirati Therapeutics Inc. | 18 mi |
| Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | 18 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | 18 mi |
| A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | Grifols Biologicals, LLC | 18 mi |
| Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 mi |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | — | argenx | 18 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) | N/A | Duke University | 18 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 18 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | 18 mi |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | 18 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) | N/A | Duke University | 18 mi |
| Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type | Phase 2 | Teikoku Pharma USA, Inc. | 18 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | 18 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | 18 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | 18 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | 18 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | 18 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | 18 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | 18 mi |
| Azithromycin for Critical Asthma - Pediatrics | Phase 2/3 | Johns Hopkins All Children's Hospital | 18 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 18 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Phase 3 | Takeda | 18 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | 18 mi |
| Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Phase 3 | GlaxoSmithKline | 18 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 2/3 | Pfizer | 18 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | 18 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | 18 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | 18 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | 18 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | 18 mi |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | 18 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | 18 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | 18 mi |
| A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | 18 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | 18 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 18 mi |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Phase 3 | Bristol-Myers Squibb | 18 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | 18 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | 18 mi |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | 18 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | 18 mi |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | 18 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | 18 mi |
| Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | Phase 2 | Merus B.V. | 18 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 18 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | 18 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 20 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | 20 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | 20 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 20 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | 20 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | 20 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 20 mi |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | 20 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | 20 mi |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | Phase 3 | AstraZeneca | 20 mi |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | 21 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | 21 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | 21 mi |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Phase 2 | Eli Lilly and Company | 21 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 21 mi |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | 21 mi |
| Prevail Global Study | N/A | Medtronic Vascular | 21 mi |
| STOP AF First Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 21 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | 21 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | 21 mi |
| Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | 21 mi |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | Phase 3 | Paradigm Biopharmaceuticals Ltd. | 21 mi |
| A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis | Phase 1 | Eli Lilly and Company | 21 mi |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Hoffmann-La Roche | 21 mi |
| A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants | Phase 1/2 | DualityBio Inc. | 21 mi |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Phase 3 | Novartis Pharmaceuticals | 21 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | 21 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | 22 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | 22 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | 22 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | 22 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | 22 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | 22 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | 22 mi |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | 22 mi |
| Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier | — | Veracyte, Inc. | 22 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | 26 mi |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Novartis Pharmaceuticals | 26 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | 26 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | 26 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 32 mi |
| Collection of Samples USOPTIVAL Study | — | Universal Diagnostics | 32 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | 32 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | 32 mi |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Phase 2 | Sun Pharmaceutical Industries Limited | 32 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | 32 mi |
| Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure | Phase 4 | Lakeland Regional Health Systems, Inc. | 32 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | 32 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 32 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | 32 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 32 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 32 mi |
| A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | 32 mi |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | 32 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 32 mi |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | Pfizer | 32 mi |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Phase 4 | Pfizer | 32 mi |
| Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center | N/A | Medaxis, LLC | 32 mi |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Phase 3 | Novo Nordisk A/S | 32 mi |
| A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction | Phase 1 | Novartis Pharmaceuticals | 32 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | 32 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | 32 mi |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) | Phase 2 | Connect Biopharm LLC | 32 mi |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | Phase 2 | Connect Biopharm LLC | 32 mi |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Phase 3 | Zenas BioPharma (USA), LLC | 32 mi |
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Phase 3 | Zenas BioPharma (USA), LLC | 32 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | 32 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | 32 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | 32 mi |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | Phase 1/2 | AVM Biotechnology Inc | 40 mi |
| Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | Phase 3 | GlaxoSmithKline | 42 mi |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Phase 1 | Whitehawk Therapeutics, Inc. | 43 mi |
| ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Phase 1/2 | Adagene Inc | 43 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | 43 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | 43 mi |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Day One Biopharmaceuticals, Inc. | 43 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) | Phase 1 | Hoffmann-La Roche | 43 mi |
| Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 43 mi |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Phase 1/2 | Daiichi Sankyo | 43 mi |
| Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | — | Mayo Clinic | 43 mi |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | Phase 1 | Daiichi Sankyo | 43 mi |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | 43 mi |
| A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System | N/A | Pulse Biosciences, Inc. | 43 mi |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | 43 mi |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Phase 1/2 | D3 Bio (Wuxi) Co., Ltd | 43 mi |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | Phase 4 | Eli Lilly and Company | 43 mi |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Phase 2 | Nurix Therapeutics, Inc. | 43 mi |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 43 mi |
| A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | Phase 1 | Stemline Therapeutics, Inc. | 43 mi |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 1 | Bristol-Myers Squibb | 43 mi |
| A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | OnCusp Therapeutics, Inc. | 43 mi |
| A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | 43 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 43 mi |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | 43 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | 43 mi |
| A Study of YL242 in Subjects With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 43 mi |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Phase 4 | Eli Lilly and Company | 43 mi |
| A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study of DS5361b in Participants With Advanced Solid Tumors | Phase 1 | Daiichi Sankyo | 43 mi |
| A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Phase 1/2 | Step Pharma, SAS | 43 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | 43 mi |
| A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | Phase 1/2 | Selecxine | 43 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | 43 mi |
| Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma | N/A | M.D. Anderson Cancer Center | 43 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | 43 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Genentech, Inc. | 43 mi |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | 43 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 43 mi |
| A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Phase 1 | Eli Lilly and Company | 43 mi |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Phase 3 | Genelux Corporation | 43 mi |
| A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Halda Therapeutics OpCo, Inc. | 43 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 43 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine | Phase 2 | AbbVie | 43 mi |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Erasca, Inc. | 43 mi |
| A Study of PYX-201 in Advanced Solid Tumors | Phase 1 | Pyxis Oncology, Inc | 43 mi |
| A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Phase 1 | Accutar Biotechnology Inc | 43 mi |
| CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Crescent Biopharma, Inc. | 43 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | 43 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | 43 mi |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | Phase 1/2 | Perspective Therapeutics | 43 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | 43 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 43 mi |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| [18F]PI-2620 Phase 3 Histopathological Study | Phase 3 | Lantheus Biosciences Ltd. | 43 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation | — | Heart Rhythm Clinical and Research Solutions, LLC | 43 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | 43 mi |
| Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System | — | Kansas City Heart Rhythm Research Foundation | 43 mi |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | 43 mi |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Phase 2 | Regeneron Pharmaceuticals | 43 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | 43 mi |
| The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. | — | Heart Rhythm Clinical and Research Solutions, LLC | 43 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | 43 mi |
| Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System | N/A | DT MedTech, LLC | 43 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | 43 mi |
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | Phase 1 | MBQ Pharma | 43 mi |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Phase 1 | Accent Therapeutics | 43 mi |
| A Study of HLD-0117 in Patients With Metastatic Breast Cancer | Phase 1 | Halda Therapeutics OpCo, Inc. | 43 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | 43 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 43 mi |
| A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | Phase 1 | Edgewood Oncology Inc. | 43 mi |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Phase 1/2 | Apollo Therapeutics Ltd | 43 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | 43 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | 43 mi |
| Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Phase 1 | Circle Pharma | 43 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | 43 mi |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 43 mi |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 43 mi |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Phase 1 | Olema Pharmaceuticals, Inc. | 43 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 43 mi |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Phase 1 | Sutro Biopharma, Inc. | 43 mi |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Phase 1 | Compass Therapeutics | 43 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | 43 mi |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Phase 1 | Dren Bio | 43 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | 43 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | 43 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 45 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 45 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | 45 mi |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | AbbVie | 45 mi |
| Development and Analysis of a Stool Bank for Cancer Patients | — | Persephone Biosciences | 45 mi |